Piché A
Département de Microbiologie, Université de Sherbrooke, Sherbrooke, Québec.
Can J Infect Dis. 1999 Jul;10(4):307-12. doi: 10.1155/1999/914379.
Despite significant advances in the treatment of human immunodeficiency virus (HIV) infection in the past 10 years, it remains an incurable disease. The inability of traditional drug-based therapies to inhibit HIV replication effectively for extended periods of time has stimulated intense research to develop novel approaches for this disease. Current understanding of HIV molecular biology and pathogenesis has opened the way for the development of gene therapy strategies for HIV infections. In this context, a number of intracellular immunization-based strategies have been evaluated, and some of them have reached the stage of phase I/II human clinical trials. These strategies include the use of single-chain antibodies, capsid-targeted viral inactivation, transdominant negative mutants, ribozymes, antisense oligonucleotides and RNA decoys. While a number of issues remain to be studied before intracellular immunization can be applied to the treatment of HIV infections, the significant progress already made in this field is likely to lead to clinical applications.
尽管在过去十年中人类免疫缺陷病毒(HIV)感染的治疗取得了重大进展,但它仍然是一种无法治愈的疾病。传统的基于药物的疗法无法长时间有效抑制HIV复制,这激发了人们对开发针对该疾病的新方法进行深入研究。目前对HIV分子生物学和发病机制的了解为开发针对HIV感染的基因治疗策略开辟了道路。在这种背景下,已经评估了许多基于细胞内免疫的策略,其中一些已经进入了I/II期人体临床试验阶段。这些策略包括使用单链抗体、衣壳靶向病毒灭活、显性负突变体、核酶、反义寡核苷酸和RNA诱饵。虽然在细胞内免疫应用于HIV感染治疗之前仍有许多问题有待研究,但该领域已经取得的重大进展可能会带来临床应用。